
|Articles|September 1, 2017
- Pharmaceutical Executive-09-01-2017
- Volume 37
- Issue 9
Pharmaceutical Executive, September 2017 Issue (PDF)
Click the title above to open the Pharmaceutical Executive September 2017 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 8 years ago
Pharm Exec's 16th Annual Industry Auditover 8 years ago
The Supply Chain: What Price Patient Centricity?over 8 years ago
Drug Serialization for DSCSA Compliance Benefits Everyoneover 8 years ago
Pharm Exec's 16th Annual Industry Audit (Overview)over 8 years ago
You Are Pharmaover 8 years ago
Leading With Patients in Mind: Cynthia Schwalmover 8 years ago
FDA, Industry Prepare for New User Fee Initiativesover 8 years ago
Data Inflection Pointover 8 years ago
UK Unveils Post-Brexit Life Sciences Strategyover 8 years ago
Seizing the Opportunity in STEMNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
How Are Regulatory Factors Impacting Biosimilars
2
Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement
3
Obsidian Therapeutics and Galera Therapeutics Enter $350 Million Merger Agreement
4
Pharma Finance Roundup: Platform Innovation Drives Biotech Investment Across Oncology and Immunology
5




